Purple Biotech (PPBT) Cash & Current Investments (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Cash & Current Investments data on file, last reported at $6.4 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $6.4 million, down 2.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (down 2.9% YoY), and the FY2025 annual result was $8.3 million, up 7.58% from the prior year.
• Cash & Current Investments slipped to $6.4 million in Q1 2026 per PPBT's latest filing, from $9.6 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $39.5 million in Q1 2022 and troughed at $6.3 million in Q3 2024.
• A 5-year average of $16.1 million and a median of $15.3 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments slumped 67.24% in 2022, then jumped 66.31% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $15.5 million in 2022, then slipped by 0.79% to $15.3 million in 2023, then slumped by 49.96% to $7.7 million in 2024, then grew by 24.73% to $9.6 million in 2025, then tumbled by 32.88% to $6.4 million in 2026.
• Business Quant data shows PPBT's Cash & Current Investments at $6.4 million in Q1 2026, $9.6 million in Q4 2025, and $10.5 million in Q3 2025.